Accessibility Menu
Impact BioMedical logo

Impact BioMedical(NYSEMKT) IBO

Market Cap$47.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-83%
5 YearN/A
1 Year-24%
1 Month+4%
$0.46
+3.92%
+0.02Today
Impact BioMedical last closing stock price
MetricPriceDate
Last closeUSD 0.442026-08-28
Impact BioMedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.56%USD 0.482026-08-21
1 month+4.03%USD 0.432026-07-29
3 month-14.67%USD 0.522026-05-29
Year to date-12.14%USD 0.512025-12-31
1 year-24.47%USD 0.592025-08-28
Since inception-83.44%USD 2.682024-09-16

Impact BioMedical Financials at a Glance

Market Cap

$47.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.00K

Net Income (TTM)

$789.00K

EPS (TTM)

-$0.10

P/E Ratio

-4.52

Dividend

$0.00

Beta (Volatility)

-9.84 (Low)

Price

$0.46

Volume

8,407.091

Open

$0.44

Previous Close

$0.46

Daily Range

$0.44 - $0.47

52-Week Range

$0.37 - $0.83

Estimated Earnings Date

May 12, 2026

IBO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Impact BioMedical

Impact BioMedical develops health products that address chronic diseases and everyday wellness. Its air purification and sugar-replacement technologies target common health and environmental concerns. The company’s offerings aim to help consumers, healthcare providers, and manufacturers manage health risks and improve quality of life.

Products and Services

  • Air Purification (Celios): Patented filtration system for cleaner indoor air; 100% of 2025 revenue.
  • Linebacker: Small molecule compounds for cancer, inflammation, and neurological disorders; licensed to pharmaceutical partners.
  • Laetose: Sugar and inositol blend designed to lower calorie and blood sugar impact; targets food and beverage makers.
  • Functional Fragrance (3F): Botanical-based fragrances with antimicrobial and insect-repellent uses; for consumer goods and personal care.
  • Equivir/Equivir G: Polyphenol blends with antiviral properties; licensed for over-the-counter wellness products.

Growth and Expansion

  • Acquired Celios Air Purification technology in 2025, expanding into air quality solutions.
  • Licensed Linebacker and Equivir to ProPhase Laboratories for global commercialization.
  • Partnered with Chemia Corporation to develop and patent functional fragrance products.
  • Announced merger with Dr. Ashleys Limited in 2025, combining pharmaceutical manufacturing with its patent portfolio.
  • Converted $15 million in debt to equity in 2025, eliminating non-trade debt obligations.

What Makes Impact BioMedical Stand Out

Impact BioMedical holds 69 issued and over 60 pending patents worldwide, covering a broad range of health and wellness technologies. The company’s business model centers on licensing intellectual property and forming strategic partnerships for commercialization.

Five Things You Need to Know

  • Revenue was $32,000 in 2025, up from $0 in 2024.
  • Net loss was $11.87 million in 2025, down 52% from 2024.
  • Operating loss was $4.28 million in 2025, down 85% year-over-year.
  • Cash flow from operations improved 64.7% in QQ3 2025 versus QQ3 2024.

Bottom Line

Impact BioMedical has shifted from research to commercializing patented health technologies. The company’s focus on licensing and partnerships is a central part of its business model.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

8

CEO

Frank D. Heuszel, CPA

Website

www.impactbiomedinc.com

Headquarters

Houston, TX 77084, US

IBO Financials

Key Financial Metrics (TTM)

Gross Margin

-1111.43%

Operating Margin

-14562.86%

Net Income Margin

2254.29%

Return on Equity

13.70%

Return on Capital

-33.86%

Return on Assets

4.71%

Earnings Yield

-22.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$47.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

107.82M

Volume

8.41K

Avg. Volume

52.50K

Financials (TTM)

Gross Profit

-$389.00K

Operating Income

-$5.10M

EBITDA

-$401.00K

Operating Cash Flow

-$508.00K

Capital Expenditure

$0.00

Free Cash Flow

-$508.00K

Cash & ST Invst.

$10.00K

Total Debt

$0.00

Impact BioMedical Performance Analysis

Impact BioMedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 32,000N/A
Impact BioMedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30157.1%
Q42025-12-31-61.1%
Q12026-03-31N/A
Q22026-06-30-57.1%
Impact BioMedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.61441.0%
20232023-12-31USD -0.38-38.5%
20242024-12-31USD -2.15469.9%
20252025-12-31USD -0.38-82.5%
Impact BioMedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3089.8%
Q42025-12-31141.8%
Q12026-03-31-142.3%
Q22026-06-3069.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.00K

-57.1%

Gross Profit

$2.00K

-66.7%

Gross Margin

66.67%

N/A

Market Cap

$47.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.92M

N/A

Employees

2

N/A

Net Income

-$699.00K

+95.1%

EBITDA

-$418.00K

+97.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$10.00K

-98.4%

Total Debt

$0.00

-100.0%

Accounts Receivable

$197.00K

-1.5%

Inventory

$62.00K

-87.2%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

4.71%

N/A

Return on Invested Capital

-34.67%

N/A

Free Cash Flow

$470.00K

+167.7%

Operating Cash Flow

$470.00K

+167.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics, Inc.
$3.68-2.90%
NRSNNeuroSense Therapeutics Ltd.
$0.43+1.50%
QNRXQuoin Pharmaceuticals, Ltd.
$6.22+1.63%
BCLIBrainstorm Cell Therapeutics Inc.
$1.03-6.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About IBO

What is the current price of Impact BioMedical?

Impact BioMedical is trading at $0.46 per share.

What is the 52-week range for Impact BioMedical?

Over the past 52 weeks, Impact BioMedical has traded between $0.37 and $0.83.

How much debt does Impact BioMedical have?

As of the most recent reporting period, Impact BioMedical reported total debt of $0.00.

How much cash does Impact BioMedical have on hand?

Impact BioMedical reported $10.00K in cash and cash equivalents in its most recent financial results.

What is Impact BioMedical’s dividend yield?

Impact BioMedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services